Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: Up to 25% of patients with myelofibrosis have platelet counts below 100,000 at presentation. Patients with thrombocytopenia are more likely to be anemic and PRBC transfusion-dependent, as well as have high-risk disease characteristics and a poor overall survival rate. Among all JAK inhibitors studied in phase 3 clinical trials, pacritinib seems not to induce significant thrombocytopenia while maintaining a good spleen response. Severe thrombocytopenia is a major impediment to myelofibrosis therapy, and more research, particularly on novel therapeutic agents aimed at cytopenic patient populations, is needed.
|
Authors | Musa Yilmaz, Srdan Verstovsek |
Journal | Expert review of hematology
(Expert Rev Hematol)
Vol. 15
Issue 3
Pg. 233-241
(03 2022)
ISSN: 1747-4094 [Electronic] England |
PMID | 35316110
(Publication Type: Journal Article, Review)
|
Chemical References |
- Janus Kinase Inhibitors
- Protein Kinase Inhibitors
|
Topics |
- Anemia
(diagnosis, etiology, therapy)
- Humans
- Janus Kinase Inhibitors
(pharmacology)
- Primary Myelofibrosis
(complications, diagnosis, drug therapy)
- Protein Kinase Inhibitors
(adverse effects)
- Thrombocytopenia
(diagnosis, drug therapy, etiology)
|